Core Insights - The company is focused on improving financial performance through operational discipline and strategic initiatives aimed at enhancing profitability and quality of care [3][4][18] - The 2026 outlook anticipates revenue between $5.41 billion and $5.58 billion, with a medical margin of $300 million to $350 million, reflecting disciplined contracting and improved payer relationships [5][30][27] - The company expects to benefit from enhanced data capabilities and clinical pathways to manage chronic diseases, which are anticipated to improve patient outcomes and reduce costs [6][10][28] Financial Performance - For 2025, the company reported total revenue of $5.93 billion, with a medical margin of negative $57 million and adjusted EBITDA of negative $296 million, primarily due to elevated medical costs and market exits [20][22] - The medical cost trend for 2025 was adjusted to approximately 6.5%, with a fourth-quarter trend of 7.4% due to increased inpatient stays and high-cost claims [21][40] - The company ended 2025 with 511,000 Medicare Advantage members and 114,000 ACO REACH members, reflecting a cautious growth strategy [20][25] Strategic Initiatives - The company has prioritized economic sustainability over membership growth, opting to exit unprofitable payer contracts and restructure arrangements to focus on care coordination fee models [7][9] - Clinical pathways have been advanced to proactively manage high-impact chronic conditions, with over 90% of the network adopting heart failure programs [10][11] - Quality initiatives are being enhanced, with a focus on improving STAR measures, which are critical for value-based care success [12][13] Market Outlook - The company anticipates a strong improvement in medical margin and adjusted EBITDA in 2026, supported by renegotiated contracts and a focus on quality performance [16][30] - The 2026 payer bids are expected to reflect improved profitability, with anticipated changes in benefit design that could positively impact cost trends [29][30] - The company is preparing for potential challenges in 2027, including further contract adjustments and ongoing management of cost trends [44][46] Regulatory Environment - The company expressed disappointment with the CMS Advance Rate Notice, believing it does not adequately address rising costs and utilization trends [34][35] - The company is actively analyzing the implications of the risk model changes and expects minimal impact due to its strong primary care partnerships [35][66] - The upcoming LEAD program from CMS is viewed positively, as it emphasizes long-term value-based care and could support sustained investment [14][46]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $1.57 billion, and for the full year 2025, it was $5.93 billion, reflecting lower than expected risk adjustment revenue and market exits [21][22] - Medical margin for Q4 was negative $74 million and negative $57 million for the full year, impacted by elevated cost trends and market exits [22][23] - Adjusted EBITDA was negative $142 million for Q4 and negative $296 million for the full year, with ACO REACH performance aligning with expectations [23][24] Business Line Data and Key Metrics Changes - Medicare Advantage membership at the end of 2025 was 511,000, while ACO REACH membership was 114,000, affected by a measured growth approach and market exits [20][21] - The company expects membership to reduce to approximately 430,000 in 2026, including 25,000 members in care coordination fee arrangements [11][25] Market Data and Key Metrics Changes - The medical cost trend for 2025 was approximately 6.5%, with Q4 cost trends recorded at 7.4% due to elevated inpatient stays [22][28] - The company anticipates a gross cost trend of 7.5% for 2026, reflecting ongoing elevated costs and adjustments in payer bids [28][29] Company Strategy and Development Direction - The company is focused on operational discipline and enhancing its Total Care Model, aiming for sustainable performance and long-term growth through partnerships with community-based physicians [6][7] - Strategic initiatives include improving clinical pathways, quality programs, and data-driven performance to support value-based care [7][12] - The company plans to exit unprofitable payer contracts and prioritize economic sustainability over membership growth [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment with the CMS Advance Notice, believing it does not adequately reflect rising costs and utilization trends [32][33] - The company expects significant improvement in profitability in 2026, driven by disciplined contracting and enhanced data capabilities [18][29] - Management remains optimistic about the potential for improved performance through ongoing transformation initiatives and better alignment with payer contracts [30][31] Other Important Information - The company executed $35 million in operating cost reductions in 2025, exceeding previous expectations, and plans to continue optimizing its cost structure [16][29] - The company ended 2025 with $285 million in cash and marketable securities, positioning itself for continued execution of transformation initiatives [24][31] Q&A Session Summary Question: Clarification on cost trends for 2025 - Management noted that elevated inpatient stays in Q3 led to an increase in cost trends, adjusting Q4 to 7.4% [36][37] Question: Insights on inpatient costs and future trends - Management indicated that increased inpatient costs were not concentrated in specific markets and that they took a prudent approach to reserve for Q4 [46][47] Question: Opportunities for further cost reductions - Management acknowledged ongoing opportunities for cost reduction, particularly through automation and technology [48] Question: Update on ACO REACH fee-for-service trends - Management reported that the fee-for-service cost trend has decreased slightly to 8.1% [55] Question: Membership mix and margin recovery - Management stated that the membership mix is not expected to change significantly heading into 2026 [60] Question: Quality incentives and performance targets - Management expressed confidence in achieving quality performance targets and noted that the opportunity for incentives has doubled for 2026 [63][64] Question: Comments on the Advance Notice and risk model changes - Management emphasized the need for rates that reflect actual cost trends and expressed hope for adjustments in the final rate notice [57][70]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $1.57 billion, and for the full year 2025, it was $5.93 billion, reflecting lower than expected risk adjustment revenue and market exits [21][22] - Medical margin for Q4 was negative $74 million and negative $57 million for the full year, impacted by elevated cost trends and market exits [22][23] - Adjusted EBITDA was negative $142 million for Q4 and negative $296 million for the full year, with ACO REACH performance aligning with expectations [23][24] Business Line Data and Key Metrics Changes - Medicare Advantage membership at the end of 2025 was 511,000, while ACO REACH membership was 114,000, affected by a measured growth approach and market exits [20][21] - The company expects Medicare Advantage membership to be approximately 430,000 in 2026, including 25,000 members in care coordination fee arrangements [25][29] Market Data and Key Metrics Changes - The medical cost trend for 2025 was approximately 6.5%, with Q4 trends recorded at 7.4% due to elevated inpatient costs [22][28] - The company anticipates a gross cost trend of 7.5% for 2026, reflecting ongoing elevated costs and adjustments in payer bids [28][29] Company Strategy and Development Direction - The company is focused on operational discipline and enhancing its Total Care Model, aiming for sustainable performance and long-term growth through partnerships with community-based physicians [6][7] - Strategic initiatives include improving clinical pathways, quality programs, and data-driven performance to support value-based care [7][12] - The company plans to continue its disciplined approach to contracting, prioritizing economic sustainability over membership growth [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment with the CMS Advance Notice, believing it does not adequately reflect rising costs and utilization trends [32][33] - The company expects significant improvement in profitability in 2026, driven by disciplined contracting and enhanced data capabilities [18][24] - Management remains optimistic about the potential for improved performance through ongoing transformation initiatives and strategic investments [16][31] Other Important Information - The company executed $35 million in operating cost reductions in 2025, exceeding previous expectations, and plans to optimize its cost structure further [16][29] - The company ended 2025 with $285 million in cash and marketable securities, positioning it well for future growth [24][31] Q&A Session Summary Question: Clarification on cost trends for 2025 - Management confirmed that elevated inpatient stays in Q3 led to an increase in cost trends, adjusting Q4 to 7.4% based on limited claims visibility [36][37] Question: Incremental inpatient costs and future trends - Management indicated that increased inpatient costs were not concentrated in specific markets and that they took a prudent approach to reserve for Q4 [46][47] Question: Opportunities for further cost reductions - Management acknowledged ongoing opportunities for cost reduction, particularly through automation and technology [48] Question: Update on ACO REACH fee-for-service trends - Management reported that the fee-for-service cost trend has decreased slightly to 8.1% from 8.5% [55] Question: Membership mix and margin recovery - Management stated that the membership mix is not expected to change significantly heading into 2026, with no substantial shifts anticipated [60] Question: Quality incentives and performance targets - Management expressed confidence in achieving quality performance targets for 2025 and outlined strategies for doubling incentives in 2026 [64][66] Question: Comments on the Advance Notice and risk model changes - Management emphasized the need for rates that reflect actual cost trends and expressed hope for adjustments in the final rate notice [57][70]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $1.57 billion, and for the full year 2025, it was $5.93 billion, reflecting lower than expected risk adjustment revenue and market exits [21][22] - Medical margin for Q4 was negative $74 million and negative $57 million for the full year, impacted by elevated cost trends and risk adjustment effects [23] - Adjusted EBITDA was negative $142 million for Q4 and negative $296 million for the full year, with ACO REACH performance aligning with expectations [24][30] Business Line Data and Key Metrics Changes - Medicare Advantage membership at the end of 2025 was 511,000, while ACO REACH membership was 114,000, affected by a measured growth approach and market exits [20] - The company expects to reduce membership to approximately 430,000 in 2026, including 25,000 members in care coordination fee arrangements [11][26] Market Data and Key Metrics Changes - The company anticipates a gross cost trend of 7.5% for 2026, with net cost trends expected to remain elevated at approximately 7% [29] - The 2026 outlook reflects expected positive impacts from payer contracting, clinical programs, and premium increases, with a projected revenue range of $5.41 billion to $5.58 billion [27][30] Company Strategy and Development Direction - The company is focused on operational discipline and enhancing its Total Care Model, emphasizing partnerships with community-based physicians [5][6] - Strategic initiatives include improving data visibility, clinical pathways, and cost management to support long-term value-based care success [10][19] - The company plans to continue its transformation efforts, aiming for significant profitability improvements in 2026 [19][34] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment with the CMS Advance Notice, believing it does not adequately address rising costs and utilization trends [33] - The company is optimistic about its ability to deliver significant growth and profitability in 2026, driven by actions taken in 2025 [25][32] Other Important Information - The company executed $35 million in operating cost reductions, exceeding previous expectations, to support business objectives [17][30] - The company ended 2025 with $285 million in cash and marketable securities, ahead of expectations [24][32] Q&A Session Summary Question: Clarification on cost trends for 2025 - Management noted that higher inpatient stays in Q3 led to an increase in cost trends, adjusting Q4 to 7.4% [38][39] Question: Insights on ACO REACH and future actions - Management indicated that actions for 2027 would include continued contracting and burden of illness programs, with a focus on improving margins [42][43] Question: Update on fee-for-service trends within ACO REACH - The fee-for-service cost trend has decreased from 8.5% to 8.1%, with trends concentrated in the back half of the year [58][59] Question: Special Needs Plans exposure - Current exposure to Special Needs Plans is around 7%, with no significant mix shift identified yet [80] Question: Membership exits and recontracting - Management stated that exits were broad-based and not concentrated in specific payers, with a focus on future contract negotiations [85][87]

Financial Data and Key Metrics Changes - The total revenue for Q2 2025 was $1.4 billion, down from $1.48 billion in Q2 2024, primarily due to lower risk adjustment contributions and unfavorable developments in Part D [29][30] - The medical margin for Q2 2025 was negative $53 million, compared to a positive $106 million in Q2 2024, driven by underperformance in the burden of illness program [30][32] - Adjusted EBITDA for Q2 2025 was negative $83 million, compared to negative $3 million in Q2 2024, reflecting the impact of lower risk adjustments and unfavorable prior period developments [32] Business Line Data and Key Metrics Changes - Medicare Advantage membership at the end of Q2 2025 was 498,000, down from 513,000 in Q2 2024, reflecting a measured approach to membership growth [28] - ACO REACH membership in Q2 2025 was 116,000, down from 132,000 in 2024, aligning with expectations [28] Market Data and Key Metrics Changes - The company reported a medical cost trend of 5.9% for Q2 2025, consistent with the previous year's trend of 6% [33] - The company has successfully reduced its exposure to Medicare Part D, with less than 30% of its membership carrying Part D risk in 2025 [34] Company Strategy and Development Direction - The company is focused on improving contract economics and bid visibility with payers, enhancing its data platform, and reducing variability in its business [35] - The leadership transition aims to strengthen execution and improve relationships critical to future success [11][12] - The company is committed to enhancing performance and positioning itself for sustainable value creation, particularly with the improved Medicare reimbursement model expected to take effect next year [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2025 is a transition year with challenges that were more acute than previously expected, leading to underperformance [9][10] - The company expects to see the results of strategic initiatives in 2026, with a focus on improving operational and financial performance [16][17] - Management expressed confidence in the long-term value of the company's model and its ability to deliver significant growth opportunities [10][15] Other Important Information - The company has withdrawn its previously issued full-year 2025 financial guidance due to ongoing market uncertainties [34] - The leadership team is recalibrating the organization's culture to emphasize urgency, accountability, and performance [12] Q&A Session Summary Question: Clarification on potential positive PYD in Q3 and growth rate into 2026 - Management indicated that there was a small amount of favorable development on quality programs, but the significant negative developments were related to risk adjustment and Part D costs [39][40] Question: Call trends and cost trends development - Management confirmed that Q1 cost trends were around 6%, and Q2 trends were consistent with Q1, but July data was less complete [44] Question: 2026 class commentary and glide path strategy - Management stated that growth for 2026 is under review and they will be highly selective on future growth due to current business performance [57] Question: 2026 bidding insights - Management noted that payers are looking for improved economics as they head into 2026, and negotiations are ongoing [59][62] Question: CEO search criteria - The company is looking for a CEO with multi-market management capability, experience with primary care physicians, and strong operational rigor [67] Question: Quality incentives and their impact - Management highlighted that payers are increasingly willing to include more quality incentives in contracts, which could lead to increased dollars available for performance [72][73]